首页> 美国卫生研究院文献>Frontiers in Immunology >Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses
【2h】

Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses

机译:洞悉类收费受体与γδT细胞反应之间的关系的见解。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The tumor microenvironment is an important aspect of cancer biology that contributes to tumor initiation, tumor progression and responses to therapy. The composition and characteristics of the tumor microenvironment vary widely and are important in determining the anti-tumor immune response. Successful immunization requires activation of both innate and adaptive immunity. Generally, immune system is compromised in patients with cancer due to immune suppression, loss of tumor antigen expression and dysfunction of antigen presenting cells (APC). Thus, therapeutic immunization leading to cancer regression remains a significant challenge. Certain cells of the immune system, including dendritic cells (DCs) and gamma delta (γδ) T cells are capable of driving potent anti-tumor responses. The property of MHC-unrestricted cytotoxicity, high potential of cytokine release, tissue tropism and early activation in infections and malignant disease makes γδ T cells as an emerging candidate for immunotherapy. Various strategies are being developed to enhance anti-tumor immune responses of γδ T cells and DCs one of them is the use of novel adjuvants like toll like receptors (TLR) agonists, which enhance γδ T cell function directly or through DC activation, which has ability to prime γδ T cells. TLR agonists are being used clinically either alone or in combination with tumor antigens and has shown initial success in both enhancing immune responses and eliciting anti-tumor activity. TLR activated γδ T cells and DCs nurture each other’s activation. This provides a potent base for first line of defense and manipulation of the adaptive response against pathogens and cancer. The available data provides a strong rationale for initiating combinatorial therapy for the treatment of diseases and this review will summarize the application of adjuvants (TLRs) for boosting immune response of γδ T cells to treat cancer and infectious diseases and their use in combinatorial therapy.
机译:肿瘤微环境是癌症生物学的重要方面,有助于肿瘤的发生,肿瘤的进展和对治疗的反应。肿瘤微环境的组成和特征千差万别,在确定抗肿瘤免疫应答中很重要。成功的免疫需要先天免疫和适应性免疫的激活。通常,由于免疫抑制,肿瘤抗原表达的丧失和抗原呈递细胞(APC)的功能障碍,癌症患者的免疫系统受到损害。因此,导致癌症消退的治疗性免疫仍然是一项重大挑战。免疫系统的某些细胞,包括树突状细胞(DC)和γδ(γδ)T细胞,能够驱动有效的抗肿瘤反应。 MHC无限制的细胞毒性,细胞因子释放的高潜力,组织趋向性以及感染和恶性疾病的早期激活等特性使γδT细胞成为免疫疗法的新兴候选药物。正在开发出各种策略来增强γδT细胞和DC的抗肿瘤免疫反应,其中之一是使用新型佐剂,如Toll样受体(TLR)激动剂,可直接或通过DC激活来增强γδT细胞功能。启动γδT细胞的能力。 TLR激动剂在临床上可单独使用或与肿瘤抗原结合使用,并且在增强免疫应答和引发抗肿瘤活性方面均显示出初步的成功。 TLR激活的γδT细胞和DC相互促进激活。这为第一道防线和操纵针对病原体和癌症的适应性反应提供了强大的基础。现有数据为启动组合疗法治疗疾病提供了有力的依据,本综述将总结佐剂(TLR)在增强γδT细胞免疫应答以治疗癌症和传染性疾病中的应用及其在组合疗法中的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号